Go or no go? Agile and Lipocine hope to make it third time lucky
Smaller projects dominate the list, but this doesn’t make them any less important for November’s hopefuls.
Horizon looks for a new growth driver
The company plans to make the most of its head start with the Graves’ disease project teprotumumab, which is forecast to become its biggest product.
Diagnostics specialists win the US device approval race
The speediest device developer is Roche, but a look at companies’ strategies shows the perils of relying on bought-in tech.
Shock revelation sees Biogen erase its aducanumab losses
The amyloid-beta project is to be filed for Alzheimer’s, and Biogen’s market cap regains the $15bn it lost in March.
Japanese drugmakers stand out at the nine-month mark
Daiichi Sankyo’s incredible stock market performance stands out amid the usual mixed bag of fallers and risers among biopharma’s mid- and small caps.
Esmo 2019 – thyroid results strengthen selpercatinib's case
As selpercatinib confirms its activity in thyroid cancer, Eli Lilly gears up to prove the Ret inhibitor’s potential in larger trials.
Go or no go? Novartis eyes a big new growth driver
The biggest approval decision in October will involve Novartis’s eye asset Beovu, while Biogen and Alkermes face a key verdict in MS.
Alder won’t solve Lundbeck’s headaches
Lundbeck needed a deal, but it could struggle against strong competition in migraine.
ESC 2019 – Amarin hopes for guideline boost despite regulatory delay
Amarin is plugging a change in ESC guidelines to include Vascepa, but with the product’s regulatory fate undecided how much difference will this make to sales?
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.